Literature DB >> 11289116

Mechanism of specific nuclear transport of adriamycin: the mode of nuclear translocation of adriamycin-proteasome complex.

K Kiyomiya1, S Matsuo, M Kurebe.   

Abstract

Adriamycin (ADM), an anthracycline anticancer agent, is selectively stored in the nuclei of a variety of proliferating cells, but the precise mechanism of specific nuclear transport of ADM is not well known. Recently, we demonstrated that ADM shows high binding affinity to the cytoplasmic proteasomes of L1210 mouse leukemia cells and that taken up ADM by the cells selectively binds to proteasomes. Nuclear targeting of proteasome in proliferating cells may be mediated by the nuclear localization signals that are found in several of the alpha-type subunits of the 20S proteasome. To confirm nuclear transport of the ADM-proteasome complex, we synthesized a photoactive ADM analogue, N-(p-azidohenzoyl)-ADM, and generated a photoaffinity-labeled proteasome complex. The 26S proteasome purified from the cytosol of L1210 cells had a high affinity to N-(p-azidobenzoyl)-ADM. SDS-PAGE analysis of the photoaffinity-labeled proteasome showed that low molecular weight bands (approximately 21-31 kDa) of 20S proteasome had the highest photoaffinity. The photoaffinity-labeled proteasome was distributed in the cytoplasm and nuclei of digitonin-permeabilized L1210 and B-16 mouse melanoma cells in the presence of the cytosolic fraction and ATP. The rate of nuclear translocation of the proteasome was low in the absence of ATP. These results suggest that the proteasome is a specific translocator of ADM from the cytoplasm to the nucleus and that 20S proteasome components are the dominant ADM-binding sites. The nuclear transport of ADM-proteasome complex is regulated by an ATP-dependent nuclear pore-mediated mechanism.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11289116

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.

Authors:  William Guerrant; Vishal Patil; Joshua C Canzoneri; Adegboyega K Oyelere
Journal:  J Med Chem       Date:  2012-02-13       Impact factor: 7.446

Review 2.  Can Some Anticancer Treatments Preserve the Ovarian Reserve?

Authors:  Nicolas Vallet; Nicolas Boissel; Elisabeth Elefant; Florian Chevillon; Hélène Pasquer; Charlotte Calvo; Nathalie Dhedin; Catherine Poirot
Journal:  Oncologist       Date:  2021-01-29

3.  Doxorubicin causes transient activation of protein poly(ADP-ribosyl)ation in H9c2 cardiomyocytes.

Authors:  A S Efremova; S I Shram; N F Myasoedov
Journal:  Dokl Biochem Biophys       Date:  2015-10-31       Impact factor: 0.788

4.  The role of the VPS4A-exosome pathway in the intrinsic egress route of a DNA-binding anticancer drug.

Authors:  Vivien Y Chen; Maria M Posada; Levi L Blazer; Tong Zhao; Gus R Rosania
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

5.  Second Generation Small Molecule Inhibitors of Gankyrin for the Treatment of Pediatric Liver Cancer.

Authors:  Amber M D'Souza; Manu Gnanamony; Maria Thomas; Peter Hanley; Dipti Kanabar; Pedro de Alarcon; Aaron Muth; Nikolai Timchenko
Journal:  Cancers (Basel)       Date:  2022-06-22       Impact factor: 6.575

6.  Imaging of radiation effects on cellular 26S proteasome function in situ.

Authors:  James M Brush; Kwanghee Kim; James W Sayre; William H McBride; Keisuke S Iwamoto
Journal:  Int J Radiat Biol       Date:  2009-06       Impact factor: 2.694

7.  Rapid doxorubicin efflux from the nucleus of drug-resistant cancer cells following extracellular drug clearance.

Authors:  Vivien Y Chen; Maria M Posada; Lili Zhao; Gus R Rosania
Journal:  Pharm Res       Date:  2007-08-01       Impact factor: 4.200

8.  The tumor proteasome as a novel target for gold(III) complexes: implications for breast cancer therapy.

Authors:  Vesna Milacic; Q Ping Dou
Journal:  Coord Chem Rev       Date:  2009       Impact factor: 22.315

9.  Application of doxorubicin-induced rAAV2-p53 gene delivery in combined chemotherapy and gene therapy for hepatocellular carcinoma.

Authors:  Chun-Ann Chen; Cheng-Kai Lo; Bai-Ling Lin; Eric Sibley; Shiue-Cheng Tang
Journal:  Cancer Biol Ther       Date:  2007-11-21       Impact factor: 4.742

10.  Bioorthogonal release of anticancer drugs via gold-triggered 2-alkynylbenzamide cyclization.

Authors:  Kenward Vong; Tomoya Yamamoto; Tsung-Che Chang; Katsunori Tanaka
Journal:  Chem Sci       Date:  2020-09-02       Impact factor: 9.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.